A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs Sotatercept (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms STELLAR
- Sponsors Acceleron Pharma
- 25 Nov 2024 According to Merck & Co media release, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.
- 25 Nov 2024 According to Merck & Co media release, WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial
- 13 Sep 2024 This trial has been Completed in Italy, According to European Clinical Trials Database record.